Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
Changes in blood levels of surfactant protein-A (SP-A) — immune proteins most abundant in the lungs — can help predict treatment outcomes with anti-fibrotic therapies, including Esbriet and Ofev, ... Read more
Statins, a class of medications widely prescribed to lower cholesterol levels and prevent heart disease and stroke, may be an effective treatment for idiopathic pulmonary fibrosis (IPF), a study ... Read more
Boehringer Ingelheim has acquired the worldwide exclusive rights to Enleofen‘s interleukin-11 (IL-11) platform, designed for the treatment of fibrotic diseases such as pulmonary fibrosis. This newly established partnership brings ... Read more
Galecto Biotech and PharmAkea, two clinical-stage pharmaceutical companies with robust pipelines in fibrotic diseases and cancer, have merged into a single company. Following the merger, the combined company will ... Read more
People with pulmonary fibrosis living in the Mercer and Bucks County regions of New Jersey and Pennsylvania now have access to a new pulmonary rehabilitation program. The program, launched ... Read more
The Pulmonary Fibrosis Foundation (PFF) and Three Lakes Partners are joining forces in the fight against pulmonary fibrosis (PF), according to an announcement to mark National Pulmonary Fibrosis Awareness ... Read more